FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasimigton,	D.C.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-02										
Estimated average burden										
hours ner response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	Name and Address of Reporting Person* Cdwards Peter G .ast) (First) (Middle) CO AZIYO BIOLOGICS, INC. 2510 PROSPERITY DRIVE, SUITE 370					2. Issuer Name and Ticker or Trading Symbol AZIYO BIOLOGICS, INC. [AZYO] 3. Date of Earliest Transaction (Month/Day/Year) 03/08/2022						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) below) GENERAL COUNSEL					
(Street) SILVER SPRING (City)			20904 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	e) <mark>X</mark> Form f Form f	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non-	-Deriva	tive S	Securiti	es Ac	quire	ed, Dis	sposed o	f, or Be	neficial	y Owned					
			2. Transac Date (Month/Da	Execution Date,		´ C₀	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			5. Amou Securitie Beneficie Owned F	es ally following	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Co	ode V	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			(1113411 4)		
		•	Table II - D (e							osed of, convertil			Owned				•	
1. Title of Derivative Security (Instr. 3)	2. Conversion Date Derivative Security 3. Transaction Date Execution if any (Month/Day/Year)			Co	ansactic	n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
																	1	
				Co	ode V	(A)	(D)	Date Exerc		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$5.08	03/08/2022			ode V	(A) 31,00		Exerc	isable		Title Class A Common Stock	or Number of	\$0	31,000		D		
Option (Right to	\$5.08 (2)	03/08/2022		1		+	0	Exerc	isable	Date	Class A Common	or Number of Shares	\$0 \$0	31,000 8,700		D D		

Explanation of Responses:

- 1. The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.
- 2. Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.
- 3. The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than \$10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.
- 4. The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

/s/ Jeffrey Hamet, Attorney-in-03/10/2022 Fact for Peter G. Edwards

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.